摘要
本文主要对微生物来源的Hsp90抑制剂研发情况以及格尔德霉素的衍生物17-AAG(17-丙烯胺-17-去甲氧基,tanespimycin)的分子作用机制、药代动力学、毒性和治疗范围等全方位的重点介绍。并对17-AAG近年来有关研究进展进行了概述。
The research and development situation of Hsp90 inhibitor from microbial sources and the geldanamycin derivatives 17-AAG （17-allylamino - 17- demethoxy - geldanamycin, tanespimycin） molecular mechanism, pharmacokinetics, toxicity, therapeutic range and a full range of focus on the research progress about 17AAG recently were mainly introduced, and the review were summarized.
出处
《国外医药（抗生素分册）》
CAS
2016年第2期52-60,72,共10页
World Notes on Antibiotics
